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Summary
Background. Due to new therapeutic modalities and modified thera-
peutic goals outcome of patients with acromegaly may change over time
and differ by centre. We analysed treatment outcomes and mortality of
our patients with acromegaly seen between 1971 and 2003.
Method. The cohort consisted of 94 patients who had been followed
for 0.3–31 years (mean 10.6 years). Remission criteria were a normal-
ized IGF-I concentration, a nadir GH level during oral glucose load of
<1.0mg=l and a random GH value of <2.5mg=l.
Findings. Transsphenoidal surgery achieved remission in 80% of pa-
tients with micro-adenomas (<1 cm), 65% with meso-adenomas (1 cm
to <2 cm) and 27% with macro-adenomas (2 cm). Patients with meso-
adenomas operated on after 1995 tended to have a better outcome
compared to those operated on before 1995 (Remission in 83% vs.
38%). Radiotherapy resulted in disease control in 22 of 47 patients
(47%). Intramuscular depot formulation of octreotide (Sandostatin+
LAR+) led to disease control in 17 of 26 patients (65%). After multi-
modal therapy persistent acromegalic activity remained in 18% of the
patients; only one of them had an adenoma of <2 cm. The standardized
mortality ratio was 1.30 (95% CI 0.52–2.67) for patients in remission
and 1.38 (95% CI 0.51–3.00) for patients with persistent acromegalic
activity.
Conclusions. Most patients with adenomas of <2 cm can be expected
to achieve remission by transsphenoidal surgery alone. Furthermore,
virtually all patients with adenomas of <2 cm and more than 80% of
patients with adenomas of 2 cm can be expected to achieve remission
by adjuvant treatment. Aggressive multimodal therapy is critical in the
management of acromegaly reducing mortality risk close to that of the
general population.
Keywords: Acromegaly; transsphenoidal surgery; radiotherapy; out-
come; mortality.
Introduction
Acromegaly is a rare disorder with an annual incidence
of 3–4=million and a prevalence of 40–60=million pop-
ulation [3, 35]. The underlying pathology is a growth
hormone (GH)-secreting pituitary adenoma [30]. Apart
from cosmetic and orthopaedic deformities, uncontrolled
acromegaly has been reported to lead to a 2–4.8 fold
increased mortality rate, primarily caused by cardiovas-
cular and respiratory diseases [1, 8–11, 26, 33, 38].
Despite recent advances in medical treatment trans-
sphenoidal surgery is still the initial procedure of choice
in most patients with acromegaly. Persisting disease can
be controlled by conventional and stereotactic radiother-
apy, somatostatin receptor ligands, dopamine agonists
and the GH receptor antagonist pegvisomant [15].
The aims of treatment are to relieve clinical signs and
symptoms, to normalize biochemical disease markers, to
reduce tumour size while preserving pituitary function,
and to restore life expectancy to that of the general
population. Until the early 1990s patients with a post-
therapeutic GH level of <5.0 mg=l were considered to
be cured [28, 42]. Epidemiological long term studies
however showed that a more rigorous biochemical con-
trol is required to normalize the elevated mortality rate
[1, 8, 9, 26, 33, 38]. Based on these data and due to the
development of more sensitive GH assays and the in-
troduction of IGF-I measurement, increasingly stricter
remission criteria have been defined over the last decade
[24, 31, 32]. At present a nadir GH level of <1.0 mg=l
during oral glucose tolerance test and a normal age- and
gender-matched IGF-I concentration represent the bio-
chemical treatment goal [24].
Acromegaly is a slowly evolving disease. Long-term
follow-up studies are needed in order to assess disease
control based on the new remission criteria. Due to new
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therapeutic modalities and their availability in the cor-
responding countries outcome may change with time
and may be dissimilar at different centres. Most previous
studies focused on some particular aspects of the clinical
course of acromegaly and its treatment, without report-
ing comprehensive detailed long-term data containing
outcome results of all applied therapeutic modalities
and analysis of mortality. Therefore, we aimed to deter-
mine the long-term remission following transsphenoidal
surgery, radiotherapy and medical treatment in patients
with acromegaly at the University Hospital of Bern.
Secondly, mortality of acromegaly was assessed in this
cohort.
Patients and methods
Study protocol
A retrospective chart review was performed on all patients with
acromegaly seen at the Division of Endocrinology and Diabetes of the
University Hospital of Bern, Switzerland, between December 1971 and
December 2003. The investigation resulted in a cohort of 94 patients
who had been followed for 0.3–31 years (mean 10.6 years).
Endocrine evaluation and outcomes
Typical signs and symptoms associated with biochemical evidence of
GH hypersecretion led to the diagnosis of acromegaly in all patients.
Until 1994 GH was measured by radio-immuno assay (RIA) (Serono
Diagnostics, Freiburg, Germany). Between 1994 and 2002 GH was
measured by immunoradiometric assay (IRMA) (HGH MAIAclone
Serono Diagnostics, Freiburg, Germany). The intra-assay coefficient of
variation (CV) was 1.8–2.5%, the interassay CV was 2.4–2.9%, and the
sensitivity was 0.02 ng=ml. From December 2002 GH was measured by
enzyme-linked immuno-absorbent assay (ELISA) (DSL-10-1900 Active
kit, Diagnostic System Laboratories, Webster, TX, USA). The intra-
assay CV was 3.3–4.3%, the interassay CV was 6.3–6.5%, and the
sensitivity was 0.03 ng=mL. From March 1995 to December 1997
IGF-I was measured by hydrochloride acid-ethanol extraction RIA
(Nichols Institute Diagnostics, San Juan Capistrano, CA, USA). The
intra- and interassay CVs were 5.0–9.5% and 8.8–10.8%, respectively.
The sensitivity was 0.1 ng=ml. From January 1998 IGF-I was measured
by IRMA (Nichols Institute, San Juan Capistrano, CA, USA). The intra-
assay CV was 3.3–4.3%, the interassay CV was 9.3–15.8%, and the
sensitivity limit was 6 ng=ml.
Current remission status of patients was determined by reviewing the
most recent follow-up visit. Remission criteria were a normal age- and
gender-matched IGF-I concentration and either a nadir GH level during
oral glucose load of <1.0mg=l or a random GH value of <2.5mg=l.
Patients with discordant remission status are reported only for final
outcome after multimodal therapy. For analysis of different therapeutic
modalities patients with discordant remission status were considered to
be in remission. In 58 patients remission status was based on nadir=
random GH and IGF-I levels, in 29 patients on IGF-I concentrations only
and in 6 patients on nadir=random GH levels only. Remission status
could not be assessed in 1 patient who refused follow-up surveillance.
Concurrent impairments of other pituitary hormone axis were as-
sessed on the basis of laboratory evaluations and medication provided.
The second outcome in this study was vital status and cause of
death of the whole cohort. The information obtained from the medical
charts were confirmed or corrected by contacting the patients’ general
practitioner.
Tumour classification
Pituitary adenomas were classified by size on magnetic resonance
imaging, computer tomography or intraoperative findings: tumour size
of <1 cm was defined as micro-adenoma, 1 cm and <2 cm as meso-
adenoma, and 2 cm as macro-adenoma consistent with earlier reports
[2, 37].
Treatment protocol
All but seven patients underwent transsphenoidal surgery at the Uni-
versity Hospital of Bern. All operations were performed or supervised by
the same neurosurgeon (R.S.). Adjuvant treatment for those patients with
insufficient disease control was individualized on the basis of size and
localization of residual tumour, biochemical parameters, available med-
ical therapy and patient medical condition and preference.
Statistical analysis and analysis of mortality rate
Differences in proportions in achieved outcome in relation to tumour
size and other factors were investigated by calculating Fisher’s exact
two-sided P-values. A P-value of <0.05 was considered significant.
Analyses were performed using GraphPad InStat version 3.00, GraphPad
Software, San Diego, California, USA.
For the analysis of all-cause mortality, survival probabilities of all
94 patients after diagnosis were calculated using the exact dates and
accounting for censored observations (Kaplan-Meier survival analysis).
Date of outcome was date of death or date of last follow-up for censored
individuals. As certain patients were seen at the University Hospital only
after the diagnosis had been made elsewhere, these patients provided
denominator information only after they first came under observation at
the University hospital (staggered entry). Age-specific person-years of
follow-up (in 5-year age groups) were calculated and age-specific Swiss
mortality rates (in 5-year age groups) for the year 1990 were used to
calculate the expected number of deaths in this patient cohort. By
dividing the expected by the observed number of deaths we obtained
the standardized mortality ratios (with 95% confidence intervals) of
patients in remission, patients with persistent disease and the whole
cohort [13]. This part of the analysis was performed using Stata 8.2,
Stata Corporation, College Station, Texas, USA.
Results
Patient characteristics before treatment (Table 1)
Forty-eight percent were male; mean age at diagnosis
was 43.7 years (range 19.6–80.4 years). The mean time
interval between occurrence of acromegaly-specific
symptoms and the date of diagnosis was 6 years (range
1–25 years). Of those patients with known size of ade-
noma, 8 percent (n¼ 6) had a micro-adenoma (<1 cm),
29% (n¼ 21) a meso-adenoma (1 cm to <2 cm) and
63% (n¼ 45) a macro-adenoma (2 cm). Reliable
classification to micro-, meso- or macro-adenoma was
not possible in 22 patients mainly because magnetic
resonance imaging technology for exact measurement
244 R. Trepp et al.
of tumour size was not yet introduced at the time of
diagnosis.
Therapy (Table 1)
Ninety-three percent of the patients (n¼ 87) had ini-
tial pituitary surgery. Three patients, diagnosed in 1951,
1963 and 1968, were treated by conventional radiother-
apy without prior pituitary surgery. One patient with a
principally prolactin-secreting pituitary adenoma with
only moderately elevated IGF-I levels was controlled
by a dopamine agonist only. Because of advanced age
2 other patients were treated with a dopamine agonist
only. One patient refused treatment.
Radiotherapy was used in 50% (n¼ 47) and medical
treatment in 44.5% (n¼ 42) of the patients. 37.5% of the
patients (n¼ 35) were treated by transsphenoidal surgery
alone (without adjuvant therapy). Fifteen percent (n¼ 14)
received surgery combined with radiotherapy and 8.5%
(n¼ 8) surgery and medical intervention (dopamine ago-
nists and=or somatostatin analogues). Thirty-two percent
(n¼ 30) needed combination of all three modalities
(surgery, radiotherapy and medical therapy) including one
patient who was treated with the GH receptor antagonist
pegvisomant. Radiotherapy and=or medical treatment
without pituitary surgery were given in 6% (n¼ 6).
Mode of radiotherapy was conventional (three-field,
total dose of 45–50 Gy in 25 fractions) in 43 patients.
Three of them received additional stereotactic radiother-
apy [27]. Stereotactic radiotherapy without prior con-
ventional radiotherapy was performed in 4 patients.
Dose of long-acting release preparation of octreotide
(Sandostatin+ LAR+) ranged from 10 to 40 mg and was
adjusted every 2–3 months based on the response of GH
and IGF-I levels.
Remission after initial pituitary surgery (Table 2)
The success of initial transsphenoidal pituitary surgery
was related to tumour size. At last follow-up 80%
of patients with micro-adenomas (4=5), 65% with
meso-adenomas (13=20) and 27% with macro-adenomas
(12=44) were in remission after initial surgery. The pro-
portion of patients in remission was significantly higher
in patients with adenomas <2 cm compared to patients
with macro-adenomas (2 cm) (P¼ 0.02). For the total
cohort postoperative remission without additional adjuvant
therapy was achieved in 42%. Considering 18 patients
with unknown tumour size did not change overall remis-
sion. Mean follow-up after transsphenoidal surgery was
7 years (range 0.3–18.2 years) for micro-adenomas, 6.9
years (range 1.0–24.1 years) for meso-adenomas, 10.6
years (range 0.5–31 years) for macro-adenomas and
Table 1. Patient characteristics, treatment modalities and remission at
last follow-up
Number of patients %
Total 94 100
Gender
Men 45 48
Women 49 52
Age at diagnosis
20–29 years 13 14
30–39 years 23 24
40–49 years 27 29
50–59 years 18 19
60–69 years 10 11
60–80 years 3 3
Size of adenoma
Micro-adenoma (<1 cm) 6 8
Meso-adenoma (1 cm to <2 cm) 21 29
Macro-adenoma (2 cm) 45 63
Exact size unknown 22 –
Therapy
Surgery only 35 37.5
Surgery and radiotherapy 14 15
Surgery and medical therapy 8 8.5
Surgery, radiotherapy
and medical treatment
30 32
Radiotherapy only 2 2
Radiotherapy and medical treatment 1 1
Medical treatment only 3 3
No therapy 1 1
Remission at last follow-up (after multimodal therapy)
In remission 64 68.8
Persistent disease 17 18.3
Discordant 12 12.9
Unknown 1 –
Table 2. Remission after pituitary surgery in relation to tumour size and time period of surgery (brackets show number of patients in remission out of
total number of patients of the respective subgroup)
Micro-adenoma Meso-adenoma Macro-adenoma Total
1972–1995 66% (2=3) 38% (3=8) 26% (7=27) 33% (12=38)
1996–2002 100% (2=2) 83% (10=12) 29% (5=17) 55% (17=31)
Total 80% (4=5) 65% (13=20) 27% (12=44) 42% (29=69)
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9.3 years for the whole cohort. Proportion of patients in
remission reached 100%, 83%, 29% and 55% for micro-
adenomas, meso-adenomas, macro-adenomas and the total
cohort, respectively, during the period between 1996 and
2002. Compared to the previously (between 1972 and
1995) surgically treated patients a trend towards improved
outcome was seen for meso-adenomas (38% vs. 83%,
P¼ 0.06) and the total cohort (33% vs. 55%, P¼ 0.09).
Remission after radiotherapy
Radiotherapy achieved remission in 47% (22=47) of
the patients after a mean follow-up of 10.1 years (median
8.0 years, range 0.3–30 years). Of those with more than
10 years follow-up after radiotherapy 57% (12=21) were
in remission. Difference between these two proportions
was not statistically significant (P¼ 0.60). Patients in
remission after radiotherapy but still on medical treatment
were considered to have persistent disease. This group
consisted of 5 patients treated with dopamine agonist, 1
patient treated with octreotide LAR and 13 patients
treated with octreotide LAR and dopamine agonist.
Seven patients were treated by stereotactic radiother-
apy. Three of them already had conventional radio-
therapy before: one achieved remission one year after
stereotactic radiotherapy, the other two still needed
further medical treatment 4 and 7 years after the inter-
vention. Of the four patients without prior conventional
irradiation, stereotactic radiotherapy achieved remission
in one patient. Mean follow-up in this group was 13
months (range 4–16 months).
All three patients treated by initial conventional radio-
therapy without pituitary surgery achieved remission.
One of them was transiently treated with bromocriptine.
Remission with octreotide therapy
Twenty-six patients were treated with intramuscular
depot formulation of octreotide (Sandostatin+ LAR+).
Sixty-five percent (n¼ 17) achieved remission. Nineteen
patients had prior radiotherapy and 20 patients were
concomitantly treated with a dopamine agonist. Four
patients had octreotide as the only adjuvant treatment
(without radiotherapy or dopamine agonist); three of
them achieved remission.
Remission at last follow-up after multimodal
therapy (Table 1)
Overall, 69% of the patients were classified as in re-
mission at the last follow-up. 45.2% achieved complete
remission in terms of a normal age- and gender-matched
IGF-I concentration and either a nadir GH level during
oral glucose load of <1.0 mg=l or a random GH value of
<2.5 mg=l. In 20.4% IGF-I levels were normalized, but
oGTT was not performed; and in 3.2% IGF-I concentra-
tions were not available but a sufficient suppression of
GH after glucose load was achieved. 12.9% had discor-
dant results: 3.2% had elevated IGF-I levels but normal
GH suppression during oral glucose load and 9.7% had
non-suppressible GH but normal IGF-I concentrations.
Of the remaining 18.3% who did not achieve remission
(5.4% defined by elevated IGF-I and pathological oGTT,
9.7% by elevated IGF-I concentrations, 3.2% by ele-
vated random GH), only one patient had an adenoma
of <2 cm. Remission status could not be assessed in 1
patient who refused follow-up surveillance.
Concurrent pituitary function abnormalities
(Tables 3 and 4)
At the time of diagnosis, 34% of the patients had
concomitant hyperprolactinemia. Forty-five percent of
the patients had partial or complete pituitary insuffi-
ciency. Most commonly the gonadal axis was affected
(in 34%) followed by secondary hypothyroidism (17%)
and ACTH deficiency (7%). No patient with diabetes
Table 3. Concurrent function abnormalities of pituitary hormone axes
(brackets show number of patients with respective pituitary function
abnormality out of total number of patients)
Pretreatment Posttreatment
Hyperprolactinemia 34% (24=71) 9% (8=91)
Partial or complete
hypopituitarism
45% (32=71) 74% (67=91)
LH=FSH deficiency 34% (24=71) 60% (55=91)
TSH deficiency 17% (12=71) 53% (48=91)
ACTH deficiency 7% (5=71) 41% (37=91)
GH deficiency – 5% (5=91)
Permanent diabetes
insipidus
0% (0=71) 4% (6=91)
Unknown 23 patients 3 patients
Table 4. Presence of hypopituitarism after adjuvant radiotherapy
and=or medical treatment (brackets show number of patients in remis-
sion out of total number of patients of the respective subgroup)
Adjuvant treatment modality
(after transsphenoidal surgery)
Presence of
hypopituitarism
Medical therapy only 88% (7=8)
Radiotherapy only 100% (14=14)
Radiotherapy and medical treatment 83% (25=30)
Total (radiotherapy and=or medical treatment) 88% (46=52)
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insipidus was recorded prior to surgery. Posttreatment,
74% of the patients had partial or complete hypopitu-
itarism. With a prevalence of 60%, gonadal insufficiency
was the most common pituitary axis failure following
treatment. Secondary hypothyroidism was found in 53%,
ACTH deficiency in 41% of patients. Five percent devel-
oped severe growth hormone deficiency and 4% suffered
from permanent diabetes insipidus. Status of other pitui-
tary hormone axes was not recorded in 23 patients
before and in 3 patients after therapy.
Patients requiring adjuvant therapy (medical treat-
ment and=or radiotherapy) after pituitary surgery had a
prevalence of pituitary insufficiency of 88%. 100%
of patients adjuvantly treated by radiotherapy only and
88% managed on adjuvant medical treatment only
developed hypopituitarism. Adjunctive treatment using
both modalities was associated with hypopituitarism in
83% of patients.
Mortality (Fig. 1, Tables 5 and 6)
Thirteen of the 94 patients died during the follow-up
period (5 men and 8 women) at a mean age at death of
70.5 years. Six patients died from heart disease, four
from malignant disease and one in a traffic accident.
Direct cause of death was unknown in two patients.
Seven patients who died were in remission at last
follow-up (mean age at death of 70.0 years). Six patients
had persistent disease at last follow-up (mean age at
death 71.1 years). Compared to the 1990 Swiss popula-
tion, the standardized mortality ratio (SMR) for the
whole cohort was 1.34 (95% CI 0.71–2.29). The SMR
for patients in remission was 1.30 (95% CI 0.52–2.67)
and the SMR for those with persistent disease at last
follow-up was 1.38 (95% CI 0.51–3.00). Survival in
patients in remission tended to be improved compared
with patients with persistent disease (Logrank test for
equality of survivor functions of P¼ 0.09).
Discussion
The catchment area of our centre in Switzerland in-
cludes about 1 million people. The incidence of newly-
diagnosed cases of acromegaly was about 3–4 per year
which corresponds to previous reports from other coun-
tries [3, 10, 19, 35]. Gender distribution, age at diag-
nosis and time interval of symptoms until diagnosis of
the present cohort were similar to earlier reports [2, 9,
17, 23, 37]. Interestingly, our cohort consisted of a
Fig. 1. Kaplan-Meier survival probabilities of patients in remission
(a) and patients with persistent acromegalic disease activity (b). Dotted
lines indicate 95% confidence limits
Table 5. Characteristics of deceased patients with acromegaly
Gender Age at death Cause of death Remission status
at last follow-up
Male 56 years traffic accident in remission
68 years unknown in remission
73 years colorectal carcinoma in remission
75 years myocardial infarction persistent disease
82 years heart failure in remission
Female 53 years multiple myeloma persistent disease
55 years heart failure persistent disease
60 years colorectal carcinoma in remission
61 years ovarian carcinoma persistent disease
72 years heart failure in remission
80 years heart failure in remission
91 years unknown persistent disease
92 years heart failure persistent disease
Table 6. Standardized mortality ratios according to status of remission
at last follow-up
Remission status
at last follow-up
Observed
deaths
Expected
deaths
Standardized mortality
ratio (95% confidence
interval)
In remission 7 5.40 1.30 (0.52–2.67)
Persistent disease 6 4.35 1.38 (0.51–3.00)
Whole cohort 13 9.72 1.34 (0.71–2.29)
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notably larger proportion of patients with a macro-
adenoma and only relatively few patients with a micro-
adenoma. This may be due to the fact that biochemical
assays and pituitary imaging techniques were less reli-
able 20–30 years ago, and therefore, the diagnosis of a
GH-secreting micro-adenoma was more difficult at that
time. Furthermore, the awareness of primary health
physicians may have improved over the last decades
resulting in an earlier diagnosis of the disease. The fact
that all but one GH-secreting micro-adenoma were
diagnosed during the last ten years supports this
hypothesis.
Epidemiological long term studies showed that a
reduction of mean GH day curve or random GH to
<2.5 mg=l measured by RIA is required to normalize
the elevated mortality rate [1, 8, 33, 38]. The newer
more sensitive GH assays yield lower results compared
to the formerly used RIA [21]. For analysis of different
therapeutic modalities patients with discordant remis-
sion status were considered to be in remission. No
patient had discordant results in terms of a random
GH <2.5 mg=l measured by IRMA or ELISA and an
elevated IGF-I. Therefore, treatment outcome results
were not falsely improved by using the same cut-off
GH value as for measurements by RIA.
Remission after pituitary surgery as initial treatment
was significantly dependant on tumour size. Eighty
percent of patients with micro-adenomas, 65% with
meso-adenomas and 27% with macro-adenomas achieved
remission after surgery only. Despite lower numbers of
performed operations per year the outcome of transsphe-
noidal surgery in our cohort was comparable with earlier
reports of specialized centres with a single dedicated
neurosurgeon [2, 9, 17, 23, 37]. However, reliable com-
parisons between centres are difficult to make since dif-
ferences in patient populations, tumour classifications
and criteria of postoperative remission complicate com-
parisons between studies. Our results show that the cut-
off of tumour size above which surgical cure becomes
considerably less likely is around 2 cm rather than
around 1 cm, in keeping with a recently published report
[11]. Pituitary adenomas of more than 2 cm almost
always invade surrounding structures. Some of these
tumours are a priori not completely removable by neu-
rosurgery, especially when vital structures such as the
carotid arteries are enclosed.
More recent surgical procedures showed a trend
towards better outcomes. Notably, our results do not
represent early postoperative remission, but remission
after a mean follow-up of 10.5 years, thereby including
the patients with recurrent disease. Impending disease
recurrence might slightly deteriorate more recent sur-
gical results but using the current stringent remission
criteria substantial impact is unlikely [40]. The im-
provement of surgical results over time in our cohort
was mainly due to a higher remission rate for meso-
adenomas during the last seven years. Meso-adenomas
are often just confined to the sella or only moderately
invading surrounding structures. In these situations the
experience of the performing neurosurgeon is likely
to be critical for success or failure. Although the time
periods were chosen to contain a similar number of
patients according to tumour size, firm conclusion is
limited by the relatively small number of patients in
the subgroups. Moreover, the arrangement resulted in
notably different length of time periods. Nevertheless,
the suspected improvement is in keeping with earlier
reports and possibly due to the growing surgical ex-
perience and expertise over time [2, 23, 29, 38]. In
addition, improvements in preoperative imaging studies
and surgical equipment may have contributed to these
findings.
Radiotherapy resulted in disease control in 22 (47%)
of 47 patients after a mean follow-up of 10.1 years
(median 8 years, range 0.3–30 years). Patients receiving
medical treatment with octreotide or dopamine agonist
at last follow-up were considered to have persistent dis-
ease. As the effects of radiotherapy can occur years after
treatment it is conceivable that some patients received
unnecessary medical treatment. However, since we try to
omit medical treatment at least every second year fol-
lowing radiotherapy substantial impact on the present
results is unlikely. Three recently published reports
questioned the efficacy of radiotherapy when assessed
by strict biochemical remission criteria [5, 16, 43]. Our
results however are more in line with other studies that
showed achievement of remission in a substantial pro-
portion of patients (34–79%) albeit after a considerable
time interval (mean or median follow-up 5–15 years)
[7, 12, 18, 25, 34].
In seven patients stereotactic radiotherapy was per-
formed [27] and control of disease was obtained after
one year in 2 patients suggesting a more rapid achieve-
ment of safe GH levels compared with conventional
radiotherapy [4, 6, 39, 41, 44]. The small sample size
with a relatively short period of observation and the
heterogeneity of the group (i.e. three patients with pre-
vious conventional radiotherapy) do not allow firm con-
clusions about efficiency of stereotactic radiotherapy
compared to conventional radiotherapy.
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Sixty-five percent of our patients treated with octreo-
tide LAR achieved remission, in keeping with previous
reports [20]. Most of the patients had prior radiotherapy
and were concomitantly treated with a dopamine agonist;
therefore the actual effect of octreotide LAR itself might
be somewhat lower.
Administrating multimodal therapy all patients with
micro-adenomas and all but one patient with meso-
adenomas achieved remission. Uncontrollable acrome-
galic activity remained a problem in 18% of patients;
virtually all of them had invasive macro-adenomas.
These results are consistent with the results of other
specialized centres [1, 9, 11, 12, 38].
Thirteen percent of our patients showed discordant
results (i.e. adequate GH suppression and elevated
IGF-I concentrations or vice versa); 30% were assessed
by IGF-I measurement only. Taking into account other
conditions that are associated with decreased IGF-I
levels (i.e. cachexia) [21], we generally give more
weight to IGF-I levels as they reflect the integrated
effect of growth hormone secretion. Depending on the
assay methods and cut-off values used, disagreement
between random=nadir GH and IGF-I levels occurs in
up to one third of patients [21]. In some patients, dis-
cordant results may express slight persistent disease
activity, which may lead to increased morbidity and
possibly mortality [22, 36].
Partial or complete pituitary insufficiency was encoun-
tered in 45% before and in 74% after treatment. The
gonadal axis was the most common affected, followed
by the thyroidal and the adrenocortical. In the present
study a high prevalence of pituitary insufficiency was ob-
served in patients requiring adjuvant treatment after
transsphenoidal surgery irrespective of the used adjunc-
tive treatment modalities. However, the retrospective
design, the relatively small number of patients and the
overlapping treatment with both adjunctive therapeutic
modalities hinder reliable comparison. More long-term
data comparing morbidity and mortality of acromegalic
patients managed on adjuvant medical treatment with
versus without (stereotactic) radiotherapy are warranted.
Thirteen deaths occurred in our cohort, mainly due to
cardiovascular disease and neoplasia. Standardized mor-
tality ratio was 1.30 for patients in remission, 1.38 for
patients with persistent disease and 1.34 for the whole
cohort. Considering the low number of patients and the
resulting large confidence interval, the relatively low
mortality ratio in our patients with persistent disease
does not necessarily disagree with previous observa-
tions that reported up to 4.8 fold increased mortality
rates in patients with persistent acromegalic activity
[1, 8, 9, 11, 26, 33, 38]. However, the increase in mor-
tality rate is dependent on the degree of GH hyperse-
cretion [26] and most of our patients with persistent
disease had only moderate residual GH hypersecretion
possibly reflecting a more aggressive treatment approach
and=or a more comprehensive availability of adjuvant
therapeutic modalities.
Conclusions
This study suggests that most patients with adenomas
of <2 cm can be expected to achieve remission by trans-
sphenoidal surgery alone. Furthermore, virtually all
patients with adenomas of <2 cm and more than 80%
of patients with adenomas of 2 cm can be expected to
achieve remission by adjuvant treatment. The effect
of radiotherapy is similar to somatostatin analogues in
terms of biochemical disease control albeit after a long
time interval. Cardiovascular disease and neoplasia are
the most common causes of death in acromegalic pa-
tients. Aggressive multimodal therapy is critical in the
management of the disease reducing mortality risk close
to that of the general population. Advances in pharma-
cological treatment (i.e. use of pegvisomant and se-
lective somatostatin receptor agonists) and radiotherapy
(radiosurgery) may result in further improvement of
disease control.
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Comments
This paper presents a series of 94 patients with Acromegaly who were
treated by different treatment modalities during a period of 30 years.
Although this is a surgical series (only 7 out of 94 patients were not
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operated on), the adjuvant treatments such as irradiation and Octreotide
treatments are well analysed with a long period of follow-up.
The article is well written and is original in the approach to analyse
the various treatment modalities. Analysis of the rate of mortality in
acromegalic patients adds to our body of knowledge of this disease.
There are a few limitations to the study as mentioned by the authors in
the Discussion section. These are:
1. Medical treatment without surgery was given to only a few patients
2. The cohort in this study included a higher proportion than usual of
Macro-adenomas >2 cm, which may influence the rate of remission.
3. Only a few patients received Stereotactic irradiation. This is a modern
treatment modality that is not well presented among the various
options studied in this paper.
In conclusion, this is an important work that may contribute to the
understanding of the overall management of Acromegaly.
M. Hadani
Tel-Aviv
This paper is a clearly written audit of acromegaly care in a single
Swiss centre.
J. S. Bevan
Aberdeen
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